-
Electronic (PDF)
-
Site License
-
Enterprisewide
Intas Pharmaceuticals Ltd. - Product Pipeline Review - Q4 2010
Global Markets Direct, November 2010, Pages: 20
Intas Pharmaceuticals Ltd. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Intas Pharmaceuticals Ltd. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Intas Pharmaceuticals Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Intas Pharmaceuticals Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Intas Pharmaceuticals Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Intas Pharmaceuticals Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Intas Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Intas Pharmaceuticals Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Intas Pharmaceuticals Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Intas Pharmaceuticals Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Intas Pharmaceuticals Ltd. and identify potential opportunities in those areas.
List of Tables
List of Figures
Intas Pharmaceuticals Ltd. Snapshot
Intas Pharmaceuticals Ltd. Overview
Key Information
Key Facts
Intas Pharmaceuticals Ltd. – Research and Development Overview
Key Therapeutic Areas
Intas Pharmaceuticals Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Intas Pharmaceuticals Ltd. – Pipeline Products Glance
Intas Pharmaceuticals Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Intas Pharmaceuticals Ltd. – Drug Profiles
IN-ALRN-001
Product Description
Mechanism of Action
R&D Progress
IN-PHARM-002
Product Description
Mechanism of Action
R&D Progress
Intas Pharmaceuticals Ltd. – Pipeline Analysis
Intas Pharmaceuticals Ltd. – Pipeline Products by Therapeutic Class
Intas Pharmaceuticals Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Intas Pharmaceuticals Ltd., Deals Summary, 2004 to 2010
Intas Pharmaceuticals Ltd. Detailed Deal Summary
Asset Purchase
Intas Pharmaceuticals Acquires Generic Etoposide From SuperGen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
